Ras-ERK1/2 signaling contributes to the development of colorectal cancer via regulating H3K9ac

Peng Tian¹, Yanfei Zhu²†, Chao Zhang¹, Xinyu Guo¹, Peng Zhang¹ and Huanzhou Xue³*

Abstract

Backgrounds/aims: Ras is a control switch of ERK1/2 pathway, and hyperactivation of Ras-ERK1/2 signaling appears frequently in human cancers. However, the molecular regulation following by Ras-ERK1/2 activation is still unclear. This work aimed to reveal whether Ras-ERK1/2 promoted the development of colorectal cancer via regulating H3K9ac.

Methods: A vector for expression of K-Ras mutated at G12 V and T35S was transfected into SW48 cells, and the acetylation of H3K9 was measured by Western blot analysis. MTT assay, colony formation assay, transwell assay, chromatin immunoprecipitation and RT-qPCR were performed to detect whether H3K9 acetylation was contributed to K-Ras-mediated cell growth and migration. Furthermore, whether HDAC2 and PCAF involved in modification of H3K9ac following Ras-ERK1/2 activation were studied.

Results: K-Ras mutated at G12 V and T35S induced a significant activation of ERK1/2 signaling and a significant down-regulation of H3K9ac. Recovering H3K9 acetylation by using a mimicked H3K9 ac expression vector attenuated the promoting effects of Ras-ERK1/2 on tumor cells growth and migration. Besides, H3K9ac can be deacetylated by HDAC2 and MDM2-dependent degradation of PCAF.

Conclusion: H3K9ac was a specific target for Ras-ERK1/2 signaling pathway. H3K9 acetylation can be modulated by HDAC2 and MDM2-dependent degradation of PCAF. The revealed regulation provides a better understanding of Ras-ERK1/2 signaling in tumorigenesis.

Keywords: Ras, ERK1/2, H3K9ac, HDAC2, PCAF, Colorectal cancer

Background

Ras is a small GTPase, it has been considered as a control switch of ERK/MAPK pathway, and both of Ras and its downstream signaling effector ERK/MAPK can modulate the activation of PI3K, mTOR and AMPK pathways [1]. Because of that, Ras plays a pivotal role in regulating multiple cellular responses, such as proliferation, differentiation, apoptosis, senescence, metabolism [2], and even cancer initiation and progression [3]. Ras protein is encoded by three ubiquitously expressed genes: H-Ras, K-Ras and N-Ras, among which K-Ras shows significant carcinogenesis when mutated at codon 12 [4]. In this process, Glycine (G) in position of codon 12 is replaced by Cysteine (C), Aspartic acid (D), Serine (S), Arginine (R) or Valine (V). Of note, G12 V together with T35S and V45E are most widely studied mutation sites of Ras. As reported by Catalogue Of Somatic Mutations In Cancer (COSMIC), the incidence of K-Ras point mutation in human cancers is approximately 30%, with pancreatic cancer accounting for 90%, colorectal cancer for 45%, and non-small cell lung cancer for 35% (https://cancer.sanger.ac.uk/cosmic).

In eukaryotic cells, nucleosomes are composed of two each of histones H2A, H2B, H3 and H4. Recently, histone modification has been widely explored since its important role in regulating tumorigenesis [5]. In the field of histone modification, histone acetylases (HATs) and histone deacetylases (HDACs) are involved in alteration

* Correspondence: huanzhou0002@sina.com
† Peng Tian and Yanfei Zhu contributed equally to this work.
³ Department of General Surgery, Zhengzhou University People’s Hospital (Henan Provincial People’s Hospital), No.7, Weiwu Road, Zhengzhou 450003, Henan, China

Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
of the chromatin structure, of which modulating gene transcription. HDAC2, one type of HDACs, locates in nucleus and can function alone. It modulates gene expression by deacetylating the N-terminal tails of the core histones, resulting in the tightening of the chromatin, which reduces its accessibility for the transcriptional machinery [6]. Recent years, acetylation of histone H3 has become a hot topic in epigenetic regulation [7]. One of the widely studied acetylation site of histone H3 tails is histone H3 lysine 9 (H3K9), produces the acetylated lysine 9 of histone H3 (H3K9ac). H3K9ac is also essentially related to transcriptional activation in human cells, and its hypoacetylation is closely associated with the occurrence and development of multiple types of cancer [7, 8]. More interestingly, H3K9ac can be specifically modulated by HDAC2 in oligodendrocyte [9]. However, the role of H3K9ac in colorectal cancer has not been well-studied yet.

Previous studies have suggested that deregulation of Ras signaling led to aberrant histone modification, resulting in cancer development. For instance, Ras-PI3K-AKT pathway regulated histone H3 acetylation at lysine 56 (H3K56ac) via the MDM2-dependent degradation, and thus regulating tumor cells activity [10]. Another study demonstrated that Ras signaling showed oncogenic role through regulating histone covalent modifications [11]. In this study, we established a link between Ras signaling and H3K9ac modification, aiming to reveal one of the underlying mechanisms of which K-Ras point mutation contributed to colorectal cancer cells growth and migration.

Methods

Cell culture and treatment

Human colorectal cancer cell line SW48 purchased from American Type Culture Collection (Catalogue number: CCL-231®, ATCC, Manassas, VA, USA) was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco). The cells were maintained at 37 °C in a humidified atmosphere with 5% CO₂.

MG132 (95% HPLC), an inhibitor of proteasome, was purchased from Sigma-Aldrich (St. Louis, MO, USA). SW48 cells were treated by 25 μM MG132 for 0–12 h. SW48 cells were treated by 25 μM MG132 for 0–12 h. SW48 cells were treated by 25 μM MG132 for 0–12 h, and 0.5 μM and 40 nM for treating cells for 12 h.

Plasmid construction and cell transfection

The coding regions of human wild-type K-Ras and H3 were amplified by PCR and were subcloned into pEGFP-N1 plasmid (Clontech Inc., Palo Alto, CA). The amplified PCAF and HDAC2 were subcloned into pcDNA6.0/HA-tag vector (Invitrogen, Carlsbad, CA, USA). The pEGFP-K-Ras G12V/T385 construct was mutated using site-directed mutagenesis. The pEGFP-H3K9Q construct was constructed using the TaKaRa MutanBEST Kit (#D401, TaKaRa, Dalian, China). Two different sequences of siRNAs specific for HDAC2 (si-HDAC2–1 and si-HDAC2–2) were purchased from GenePharma (Shanghai, China). A non-targeting sequence was used as a negative control (si-con). Mdm2–12-MU for expression of MDM2C464A was constructed and recombination into pB/V5-His Vector (Invitrogen).

SW48 cells were seeded in 6-well plates with a density of 1×10⁵ cells/well. When 50% confluence was researched, the cells were transfected with plasmids or siRNAs by using lipofectamine 3000 (Invitrogen). At 48 h of transfection, the culture medium was replaced by the complete medium to stop transfection. Transfection efficiency was confirmed by Western blot and/or RT-qPCR.

Cell viability

The transfection SW48 cells were collected by using trypsin (Sigma-Aldrich) and were seeded in 96-well plates with a density of 5×10³ cells/well. After 48 h of incubation at 37 °C, 20 μL of MTT solution (Sigma-Aldrich) with a final concentration of 5 mg/mL was added into each well and the plates were incubated at 37 °C for another 4 h. Then, the culture medium was removed and 100 μL dimethyl sulfoxide (DMSO, Sigma-Aldrich) was added. Following 10 min of shaking in an ELISA reader (Bio-Rad Laboratories, Hercules, CA, USA), the absorbance of each well was recorded at 570 nm.

Transwell migration assay

The transfectant SW48 cells were collected and seeded in the upper side of 24-well transwell chamber with 8-μm pore filters (Costar, Boston, MA). The cells were maintained at serum-free culture medium. The lower side of the chamber was filled with 600 μL complete culture medium. After 12 h of incubation at 37 °C, the cells migrated into the lower side were fixed with methanol and stained with 0.5% crystal violet (Beyotime, Shanghai, China). The absorbance of cells that had been washed with acetic acid was measured at 570 nm.

RNA extraction and RT-qPCR

Total RNAs were extracted from the transfected cells by using the TRIzol reagent (Invitrogen). Five micrograms of total RNA was subjected to reverse transcription using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Basel, Switzerland). FastStart Universal SYBR Green Master (Roche) was used in qPCR and each qPCR was carried out in triplicate for a total of 20 μL reaction mixtures on ABI PRISM 7500 Real-time PCR System.
GAPDH served as an internal control. Data were analyzed according to the classic $2^{-\Delta\Delta Ct}$ method.

**Soft-agar colony formation assay**

Low melting agarose (Thermo Scientific®, Rockford, IL, USA) with concentration of 0.5% was placed in 6-well plates, and the plates were incubated at 4 °C for 30 min. The transfected SW48 cells were seeded in 6-well with a density of 600 cells/well, and were cultured in DMEM containing 0.33% agarose at 37 °C for 2 weeks. The number of the colonies was counted microscopically.

**Western blot**

Total protein was extracted from the transfected SW48 cells by using 1% Triton X-100 (Invitrogen) and 1 mM PMSF (pH 7.4) (Solarbio, Beijing, China) over ice for 30 min. The protein concentration was determined by BCA protein assay kit (Novagen, Madison, WI, USA). Equal amount of protein samples were subjected to SDS-PAGE and proteins were transferred onto PVDF membranes (Millipore, Bedford, MA, USA). The membranes were blocked in 130 mM NaCl, 2.5 mM KCl, 10 mM Na$_2$HPO$_4$, 1.5 mM KH$_2$PO$_4$, 0.1% Tween-20 and 5% BSA (pH 7.4) for 1 h at room temperature. Then the membranes were probed by primary antibodies overnight at 4 °C. Anti-p-ERK1/2 (MA5–15173) and anti-pCAF (MA5–11186) were purchased from Invitrogen; anti-ERK1/2 (ab17942), anti-H3K9ac (ab4441), anti-H3 (ab12079), anti-HA (ab1424), anti-GFP (ab6556), anti-actin (ab8227), anti-His (ab197049), and anti-MDM2 (ab38618) were all purchased from Abcam (Cambridge, MA). Followed by incubation with the secondary antibody for 1 h at room temperature, the positive signal was detected by using enhanced chemiluminescence (ECL) and analyzed with ImageJ 1.49 (National Institutes of Health, Bethesda, MD, USA).

**Flow cytometric analysis of cell cycle distribution**

The transfected SW48 cells in 6-well plates were cultured in serum-deprived medium for 12 h to synchronize cells to G0-phase. Then, the cells were harvested by trypsinisation, washed twice with PBS and fixed in 70% ethanol at 4 °C overnight. The cells were suspended in the solution containing 0.2 mg/mL PI (Sigma-Aldrich), 0.1% Triton X-100 (Invitrogen), and 20 μg/mL RNase A (Roche) for 30 min at room temperature in the dark. The percentage of cells in the G0, G1, S and G2/M phases of the cell cycle were analyzed by flow cytometry (FACS Calibur, Becton Dickson, San Jose, CA, USA) and ModFit software (Verity Software House, Topsham, ME, USA).

**Chromatin immunoprecipitation (ChIP)**

The transfected SW48 cells (3 × 10$^6$ cells per sample) were incubated in 1% formaldehyde for 10 min at room temperature, and the cells were collected and lysed in 200 μL SDS Lysis Buffer (Beyotime). After ultrasonication, the DNA was sheered to an average length of 200–800 bp. The samples were centrifuged at 10,000 g at 4 °C for 10 min, and the supernatant was probed by anti-H3K9ac.
and transfected into SW48 cells. Figure 1a showed that phosphorylation levels of ERK1/2 were remarkably up-regulated in Ras$^{G12V/T35S}$ group as compared to pEGFP group (transfected with an empty plasmid), indicating ERK1/2 pathway was activated by K-Ras mutated at G12V and T35S. Then, the expression changes of H3K9ac were measured by performing Western blot analysis. Results in Fig. 1b and c displayed that, K-Ras mutated at G12V and T35S significantly down-regulated H3K9ac expression ($P < 0.01$), but had no effects on H3 expression. These data suggested that Ras-ERK1/2 activation repressed the acetylation of H3 at lysine 9. In order to reveal whether H3K9 acetylation is specifically mediated by ERK1/2, four inhibitors specific for ERK1/2, MAPK, PI3K and JNK pathways were used, and the expression of H3K9ac was reassessed. As a result, we found that only the inhibitor of ERK1/2 (SCH772984) could recover H3K9ac expression following K-Ras mutation at G12V and T35S (Fig. 1d and e). No such effects were observed in cells treated with inhibitors specific for MAPK, PI3K and JNK, i.e., SB203580, LY294002 and SP600125. These findings suggested that H3K9 acetylation was specifically mediated by ERK1/2, rather than MAPK, PI3K and JNK.
Ras-ERK1/2 repressed H3K9 acetylation to promote the growth and migration of SW48 cells

Next, pEGFP-H3K9Q plasmid was constructed to mimic the acetylated H3K9, and the plasmid was co-transfected with pEGFP-K-RasG12V/T35S into SW48 cells. Transfection efficiency tested by western blotting revealed that H3K9ac expression was remarkably up-regulated by transfection with pEGFP-H3K9Q, in the presence and absence of pEGFP-K-RasG12V/T35S (Fig. 2a). MTT assay result showed that co-transfection of cells with pEGFP-K-RasG12V/T35S and pEGFP-H3 significantly increased OD-value, compared to the transfection of pEGFP-H3 alone (P < 0.001, Fig. 2b).

Of note, co-transfection of cells with pEGFP-K-RasG12V/T35S and pEGFP-H3K9Q attenuated Ras-G12V/T35S-induced evaluation of OD-value (P < 0.001). Same trends were observed in Fig. 2c and d, colony number and OD-value in migration assay were both significantly increased in Ras+H3 group compared to GFP + H3 group (P < 0.001). And they were both significantly decreased in Ras+H3K9Q group, as compared to Ras+H3 group (P < 0.01). Taken together, recovering the acetylation of H3K9 attenuated the promoting effects of Ras-ERK1/2 on tumor cells growth and migration.

Ras-ERK1/2 repressed H3K9 acetylation to affect the transcription of Ras downstream genes

Next, the involvement of H3K9ac in the transcription of Ras downstream genes was addressed. RT-qPCR data in Fig. 3a showed that the mRNA levels of CYR61 (P < 0.01), IGFBP3 (P < 0.01) and WNT16B (P < 0.05) were significantly up-regulated, while the mRNA levels of NT5E (P < 0.001), GDF15 (P < 0.01), and CDC14A (P < 0.01) were significantly down-regulated in +H3 group, as compared to GFP + H3 group. However, the alteration of these mRNAs induced in Ras+H3 group were abolished in Ras+H3K9Q group. ChIP assay results in Fig. 3b showed that H3K9ac level was reduced at the promoters of these genes (P < 0.05, P < 0.01 or P < 0.001) following the activation of Ras-ERK1/2. Based on these data, we speculated that Ras-ERK1/2 mediated the transcription of its downstream genes also via regulating H3K9 acetylation.

Silence of HDAC2 recovered H3K9 acetylation and SW48 cells phenotype

Two different sequences of siRNAs specific for HDAC2 (si-HDAC2–1 and si-HDAC2–2) were transfected into SW48 cells. The mRNA levels of HDAC2 were remarkably silenced by siRNA transfection (Fig. 4a). Additionally, protein levels of H3K9ac were obviously up-regulated by siRNA transfection, even in K-RasG12V/T35S expressing cells (Fig. 4b), suggesting H3K9 acetylation could be recovered by HDAC2 silence. Subsequently, cell viability, migration, and cell cycle progression were tested to see the effect of HDAC2 silence on SW48 cells growth and migration. Figure 4c–e demonstrated that both si-HDAC2–1 and si-HDAC2–2 remarkably attenuated the effects of Ras-ERK1/2 activation on SW48 cells viability (P < 0.01), migration (P < 0.001) and S-phase arrest. And also, the transcription of CYR61 (P < 0.01), IGFBP3 (P < 0.05), WNT16B (P < 0.05), NT5E (P < 0.001), GDF15 (P < 0.001), and CDC14A (P < 0.01) altered by Ras-ERK1/2 activation were attenuated by si-HDAC2–1 plus si-HDAC2–2 (Fig. 4f). These data suggested that silence of HDAC2 recovered the acetylation of H3K9, which in turn inhibited the growth and migratory capacities of SW48 cells.

Ras-ERK1/2 repressed H3K9 acetylation in SW48 cells via degradation of PCAF

In order to reveal how Ras-ERK1/2 repressed H3K9 acetylation, we focused on investigating PCAF, a reported upstream gene of H3K9ac [13]. Figure 5a displayed that mRNA levels of PCAF and HDAC2 were both unaffected by K-RasG12V/T35S. Figure 5b results indicated that the protein level of PCAF was down-regulated by K-RasG12V/T35S, but the protein level of HDAC2 was unaffected. These results implied that Ras-ERK1/2 post-transcriptionally down-regulated PCAF expression.
This was also confirmed in Fig. 5c, that both PCAF and H3K9ac protein expression was repressed in RasG12V/T35S group. To further confirmed whether PCAF involved in the transcription of Ras downstream genes, ChIP was performed. Results from Fig. 5d showed that all of these genes that exhibited reduced H3K9ac following Ras-ERK1/2 activation also exhibited significant reduction in PCAF binding, suggesting PCAF was responsible for Ras-ERK1/2-repressed H3K9 acetylation.

Finally, SW48 cells were treated with MG132 (a proteasome inhibitor) to confirm whether PCAF regulated H3K9ac post-transcriptionally. Figure 5e showed that MG132 remarkably reversed the reduction of PCAF in K-RasG12V/T35S-expressing cells. Results in Fig. 5f showed that H3K9ac levels were down-regulated by RasG12V/T35S after 48 h of transfection in absence of MG132. However, treating cells with 25 μM MG132 gradually recovered the expression of H3K9ac (Fig. 5g). Thus, it is possible that Ras-ERK1/2 pathway repressed H3K9 acetylation through regulating PCAF.

**Fig. 4** Silence of HDAC2 recovered H3K9 acetylation and SW48 cells phenotype. a The efficiency of siRNA-mediated HDAC2 silence was determined. b SW40 cells were transfected as indicated. The expression changes of H3K9ac were detected by Western blot analysis. c Cell viability, d migration, e cell cycle progression, and f several gene transcription were respectively assessed by MTT assay, transwell assay, flow cytometry and RT-qPCR. *P < 0.05; **P < 0.01; ***P < 0.001

---

**Ras-ERK1/2 regulated H3K9ac via MDM2-mediated PCAF degradation**

It has been reported that the E3 ubiquitin ligase MDM2 could bind to acetylases, such as p300/ already in [14]. Thus, we explored whether MDM2 was implicated in PCAF degradation in K-RasG12V/T35S-expressing cells. Figure 6a and b showed that PCAF expression was gradually repressed with MDM2 expression. However, in MDM2-mutant (MDM2-MU) transfected cells, no such down-regulations were observed in PCAF expression (Fig. 6c and d), indicating MDM2 was responsible for PCAF degradation.

Next, we established a link between H3K9ac expression and MDM2 activity to reveal whether MDM2-mediated PCAF degradation was required to modulate Ras-ERK1/2-repressed H3K9 acetylation. Figure 6e showed that, MDM2 was up-regulated, while H3K9ac was down-regulated in K-RasG12V/T35S-expressing cells. Thereafter, the expression of MDM2 was repressed in K-RasG12V/T35S-expressing cells by siRNA transfection (Fig. 6f). As a
result, we found that silence of MDM2 resulted in an up-regulation of H3K9ac in K-Ras G12V/T35S-expressing cells (Fig. 6g). Collectively, these data implied that Ras-ERK1/2 regulates H3K9ac via MDM2-mediated PCAF degradation.

Discussion

In physiological conditions, inactive Ras (GDP-bound) switches to active form (GTP-bound), and activates MEK kinase, which in turn activates ERK kinase. The activation of ERK subsequently phosphorylates a number of substrates, and thereby, modulates cell fate [15]. Although Ras acted as a control switch in the activation of many signaling pathways, it seems that ERK is one of the most important pathways which can be activated by Ras point mutation [16]. This was also confirmed in this study, that K-Ras mutated at G12V and T35S induced a significant activation of ERK1/2 signaling. Since hyperactivation of Ras-ERK signaling pathway appears frequently in cancers, this signaling has been considered as a promising target for controlling of cancers [15]. However, the molecular regulation following by Ras-ERK activation is still unclear. This work demonstrated that activation of Ras-ERK could significantly repress the acetylation of H3K9 through MDM2-dependent PCAF degradation. And also, the repressed H3K9ac contributed to colorectal cancer SW48 cells growth, migration, and the transcription of several tumor-associated genes.

Histone H3 acetylation is a well-known modification process, which is often marks for the open up of chromatin and activation of gene transcription [17]. To date, five isoforms of acetylated histone H3 proteins have been found. Depending on the acetylation sites of histone H3, they are named as histone H3 acetylation at lysine 9 (H3K9ac), 14 (H3K14ac), 18 (H3K18ac), 23 (H3K23ac) and 27 (H3K27ac). The acetylation of histone H3 has clinical diagnostic significance in many cancers, including epithelial ovarian tumor [18], hepatocellular carcinoma [19], oral cancer [8], and cervical cancer [20]. Among these acetylated histone H3, H3K9ac is the most widely studied one in cancer and other diseases. It has been suggested that H3K9 acetylation can be triggered by external stimuli, such as long-term alcohol consumption [21], and traffic-related air pollution [22]. Our study for the first time suggested that H3K9 acetylation can be specifically catalyzed by Ras-ERK1/2 signaling, rather than MAPK, PI3K and JNK signaling.

The role of H3K9ac in colorectal cancer has been sporadically studied. Lutz et al., demonstrated that high levels of H3K9ac were frequently occurred in patients with colorectal cancer [23]. Another study demonstrated...
that the expression pattern of H3K9ac was altered during aging, which is a prime risk factor of the development of colorectal cancer [24]. These two studies suggested H3K9ac as a potential target for novel treatment option of colorectal cancer. However, a contrary finding was reported by Nakazawa et al., who demonstrated that H3K9ac expression was unchanged between normal and neoplastic nuclei in the colorectal cancers [25]. Based on these previous studies, the role of H3K9ac in colorectal cancer is confusing. Herein, we attempted to study the in vitro effects of H3K9ac on colorectal cancer cells growth and migration, in order to reveal the exact function of H3K9ac in this cancer. By using a mimicked H3K9ac expression vector (H3K9Q), the expression of H3K9ac in K-RasG12V/T35S-transfected SW48 cells was recovered. As a result, the growth and migratory capacities of SW48 cells were both reduced, suggesting the acetylation of H3K9 contributed to colorectal cancer SW48 cells growth and migration following Ras-ERK1/2 activation.

There are several genes have been found to be transcriptionally regulated by H3K9ac following Ras-ERK1/2 activation in this study, further suggested H3K9ac as a downstream effector of Ras-ERK1/2 signaling. All of the studied genes are known to be closely related with tumor cells growth and migration. CYR61 expression was associated with poor prognosis in patients with colorectal cancer [26] and it promotes cancer cells proliferation, invasion, survival, and metastasis [27, 28]. In addition to CYR61, IGFBP3 [29] and GDF15 [30] are also effective predictors of outcomes in patients with colorectal cancer. WNT16B [31], NTSE [32], GPF15 [33], and CDC14A [34] are implicated in tumorigenesis via regulating tumor growth and EMT process. According to the findings reported elsewhere, CYR61 [35], NTSE [36], WNT16B [37] and GDF15 [38] were identified as oncogenes, while IGFBP3 [39] and
CDC14A were found to be tumor-suppressive genes. In the current study, the expression of CYR61, IGFBP3, WNT16B was found to be down-regulated, whereas the expression of NT5E, GDF15, CDC14A was found to be up-regulated by H3K9ac. This phenomenon indicates the impacts of H3K9ac on colorectal cancer cells are complex, since both oncogenes and tumor-suppressive genes can be up-regulated or down-regulated by H3K9ac. Additional investigations are required to further analyze the pleiotropic effects of H3K9ac on cancer.

HATs and HDACs are two kind of key enzymes in catalyzing the acetylation and deacetylation of H3. Human HDACs can be divided into several large families: HDAC I (HDAC1, 2, 3 and 8), HDAC II (HDAC4, 5, 6, 7, 9 and 10), HDAC III (Sirt1-Sirt7), and HDAC IV (HDAC11) [40]. Human HATs include TIP60, MOZ/MYST3, MORF/MYST4, HBO1/MYST2, MOF/MYST1, P300, CBP, GCN5, PCAF, and ELP3 [41]. HDAC2 is highly expressed in patients with early stages of colorectal cancer, and the elevated HDAC2 expression is associated with the poor prognosis [42, 43]. In this study, we confirmed H3K9ac can be deacetylated by HDAC2 by using siRNAs specific for HDAC2. Besides, it seems that silence of HDAC2 recovered H3K9ac expression and SW48 cells phenotype following Ras-ERK1/2 activation. And also, we indicated that H3K9ac was acetylated by PCAF. Moreover, the acetylation of H3K9 by PCAF was through a MDM2-dependent fashion.

Conclusions
In conclusion, this study demonstrated that H3K9ac was a specific target for Ras-ERK1/2 signaling pathway. H3K9 acetylation can be modulated by JHDAC2 and MDM2-dependent degradation of PCAF. The revealed regulation provides a better understanding of Ras-ERK1/2 signaling in tumorigenesis, and the findings will accelerate the development of novel targets for colorectal cancer treatments.

Acknowledgements
Not applicable.

Funding
Not applicable.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
Conceived and designed the experiments: PT, YFZ and HZX; Performed the experiments and analyzed the data: PT, YFZ, CZ and XYG; Contributed reagents/materials/analysis tools: PZ; Wrote the manuscript: PT and YFZ; Revised the manuscript: HZX. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.
18. Zhen L, Gui-lan L, Ping Y, Jin H, Ya-li W. The expression of H3K9Ac, H3K14Ac, and H4K20Me in epithelial ovarian tumors and the clinical significance. Int J Gynecol Cancer. 2010;20(1):82–6.

19. Wang W, Xu L, Kong J, Fan H, Yang P. Quantitative research of histone H3 acetylation levels of human hepatocellular carcinoma embryos. Dongwu Xue Yu. 2013(3):327–39.

20. Beyer S, Zhu J, Mayr D, Kuhn C, Schulze S, Hofmann S, Dannecker C, Jeschke U, Kost BP. Histone H3 acetyl K9 and histone H3 tri methyl K4 as prognostic markers for patients with cervical cancer. Int J Mol Sci. 2017;18(3).

21. Ding F, Chen L, Liu Y, Wu FR, Ding B, Li WW, Wang R. Effects of alcohol on H3K9 acetylation in mouse pre-implantation embryos. Dongwu Xue Yu. 2015;36(1):54–8.

22. Ding R, Jin Y, Liu X, Zhu Z, Zhang Y, Wang T, Xu Y. H3K9 acetylation change patterns in rats after exposure to traffic-related air pollution. Environ Toxicol Pharmacol. 2016;42:170–5.

23. Lutz L, Fitzner IC, Ahrens T, Geissler AL, Makowiec F, Hopt UT, Bogatyreva L, Zhang Y, Wang X, Zhang M, Zhang Z, Jiang L, Li L. GPF15 promotes epithelial-to-mesenchymal transition in colorectal carcinoma. Artif Cells Nanomed Biotechnol. 2018:1–7.

24. Wang YA, Sun Y, Palmer J, Solomides C, Huang LC, Shtyr Y, Dicker AP, Lu B. IGFBP3 modulates lung tumorigenesis and cell growth through IGF-1 signaling. Mol Cancer Res. 2017;15(7):896–904.

25. Zhang H, Shang YP, Chen HY, Li J. Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatol Res. 2016.

26. Gadhia S, Shrimp JH, Meier JL, McGee JE, Dahl Jr. HL. Histone acetyltransferase assays in drug and chemical probe discovery. In: Sittampalam GS, Cossens NP, Brmacomic K, Grossman A, Arkin MM, Lund D, Austin C, Baell J, Bejcek B, TDY C, et al., editors. Assay Guidance Manual. Bethesda: Eli Lilly & Company and the National Center for advancing translational Sciences; 2004.

27. Stypula-Cyrus Y, Damania D, Kunte DP, Cruz MD, Subramanian H, Roy AK, Backman V. HDAC up-regulation in early colon fields: epigenetics is involved in cell tumorigenesis through regulation of chromatin structure. PLoS One. 2013;8(5):e64600.

28. Weichert W, Roske A, Niesporek S, Nelson H, Kuckendahl AH, Dietel M, Geckeler V, Boehm M, Beckers T, Denkert C. H3 histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylase 6 in vitro and in vivo. Clin Cancer Res. 2008;14(6):1669–77.